Literature DB >> 27936488

Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies.

D Gómez-Martín1, A S Galindo-Feria1, A Barrera-Vargas1, J Merayo-Chalico1, G Juárez-Vega2, J Torres-Ruiz1, J Alcocer-Varela1.   

Abstract

The presence of anti-Ro52/tripartite motif 21 (Trim21) autoantibodies has been associated with a distinctive clinical profile and has gained value as a prognostic marker in idiopathic inflammatory myopathies (IIM). The aim of the present work was to analyse Ro52/Trim21 expression in different subsets of peripheral blood mononuclear cells (PBMCs) of patients with IIM, as well as the ubiquitination profile and its association with proinflammatory cytokine production. We included 18 patients with recent-onset IIM and 18 age- and gender-matched healthy donors. PBMCs were isolated and different subsets (CD4+ , CD8+ , CD14+ ) were purified by magnetic selection. The expression of Ro52/Trim21 in different PBMC subsets of patients with IIM and healthy donors was analysed by Western blot. We assessed the presence of myositis-specific and associated autoantibodies by enzyme-linked immunosorbent assay (ELISA). Cytokine levels were measured by cytometric bead array. Patients with IIM showed decreased protein expression of Ro52/Trim21 in comparison to healthy controls in PBMC (0·97 ± 0·60 versus 1·84 ± 0·92, P = 0·016), CD4+ lymphocytes (0·79 ± 0·54 versus 2·41 ± 0·78, P = 0·017), and monocytes (0·87 ± 0·35 versus 1·89 ± 0·20, P < 0·001). There were no significant differences among IIM groups. Also, a lower K48-mediated ubiquitination profile was found, predominantly in CD4+ lymphocytes. Furthermore, after mitogenic stimulation, there was a higher synthesis of proinflammatory cytokines by T cells [interleukin (IL)-17A and tumour necrosis factor (TNF)-α] and monocytes [IL-6 and interferon (IFN)-α] from IIM patients compared with healthy controls. Our data suggest that patients with IIM, mainly DM, are characterized by a deficient expression of Ro52/TRIM21 in different PBMC subsets (CD4+ lymphocytes and monocytes), along with lower K48-mediated ubiquitination, which is associated with a proinflammatory cytokine response.
© 2016 British Society for Immunology.

Entities:  

Keywords:  Ro52; Trim21; idiopathic inflammatory myopathies; peripheral blood mononuclear cells

Mesh:

Substances:

Year:  2017        PMID: 27936488      PMCID: PMC5343346          DOI: 10.1111/cei.12914

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  The E3-ligase TRIM family of proteins regulates signaling pathways triggered by innate immune pattern-recognition receptors.

Authors:  Gijs A Versteeg; Ricardo Rajsbaum; Maria Teresa Sánchez-Aparicio; Ana M Maestre; Julio Valdiviezo; Mude Shi; Kyung-Soo Inn; Ana Fernandez-Sesma; Jae Jung; Adolfo García-Sastre
Journal:  Immunity       Date:  2013-02-21       Impact factor: 31.745

2.  Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study.

Authors:  P Ghillani; C André; C Toly; A M Rouquette; D Bengoufa; P Nicaise; C Goulvestre; A Gleizes; M A Dragon-Durey; M A Alyanakian; P Chretien; S Chollet-Martin; L Musset; B Weill; C Johanet
Journal:  Autoimmun Rev       Date:  2011-04-05       Impact factor: 9.754

3.  Anti-Ro52 autoantibodies from patients with Sjögren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface.

Authors:  Alexander Espinosa; Janosch Hennig; Aurélie Ambrosi; Madhanagopal Anandapadmanaban; Martina Sandberg Abelius; Yi Sheng; Filippa Nyberg; Cheryl H Arrowsmith; Maria Sunnerhagen; Marie Wahren-Herlenius
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

Review 4.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

5.  Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway.

Authors:  Alexander Espinosa; Valerie Dardalhon; Susanna Brauner; Aurelie Ambrosi; Rowan Higgs; Fransisco J Quintana; Maria Sjöstrand; Maija-Leena Eloranta; Joan Ní Gabhann; Ola Winqvist; Birgitta Sundelin; Caroline A Jefferies; Björn Rozell; Vijay K Kuchroo; Marie Wahren-Herlenius
Journal:  J Exp Med       Date:  2009-07-27       Impact factor: 14.307

6.  Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors.

Authors:  Rowan Higgs; Elisa Lazzari; Claire Wynne; Joan Ní Gabhann; Alexander Espinosa; Marie Wahren-Herlenius; Caroline A Jefferies
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

Review 7.  The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications.

Authors:  Ellen M Moran; Frank L Mastaglia
Journal:  Neuromuscul Disord       Date:  2014-06-20       Impact factor: 4.296

8.  Sequential ubiquitination and deubiquitination enzymes synchronize the dual sensor and effector functions of TRIM21.

Authors:  Adam J Fletcher; Donna L Mallery; Ruth E Watkinson; Claire F Dickson; Leo C James
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

Review 9.  TRIM family proteins: retroviral restriction and antiviral defence.

Authors:  Sébastien Nisole; Jonathan P Stoye; Ali Saïb
Journal:  Nat Rev Microbiol       Date:  2005-10       Impact factor: 60.633

Review 10.  InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins.

Authors:  Gijs A Versteeg; Stefan Benke; Adolfo García-Sastre; Ricardo Rajsbaum
Journal:  Cytokine Growth Factor Rev       Date:  2014-08-13       Impact factor: 7.638

View more
  1 in total

1.  Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners.

Authors:  Eunate Gallardo-Vara; Lidia Ruiz-Llorente; Juan Casado-Vela; María J Ruiz-Rodríguez; Natalia López-Andrés; Asit K Pattnaik; Miguel Quintanilla; Carmelo Bernabeu
Journal:  Cells       Date:  2019-09-13       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.